Addison Capital’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.58M Buy
33,045
+4,569
+16% +$781K 0.99% 26
2025
Q4
$4.81M Buy
28,476
+23,143
+434% +$3.76M 1.2% 26
2025
Q3
$770K Buy
5,333
+2,204
+70% +$301K 0.23% 83
2025
Q2
$396K Buy
3,129
+324
+12% +$39.8K 0.14% 104
2025
Q1
$359K Buy
2,805
+1,199
+75% +$163K 0.14% 105
2024
Q4
$212K Sell
1,606
-24
-1% -$3.37K 0.08% 129
2024
Q3
$237K Buy
1,630
+164
+11% +$23.7K 0.1% 126
2024
Q2
$201K Buy
+1,466
New +$196K 0.09% 138

Other funds holding IBB

Addison Capital's IBB Position: Q1 2026 in Review

Addison Capital increased its iShares Biotechnology ETF (IBB) stake by 16% in Q1 2026, buying an estimated $781K and bringing the position to 33,045 shares worth $5.58M. The position accounts for 0.99% of the portfolio, ranked #26.

Addison Capital first reported a position in IBB in Q2 2024 and has held it in 8 quarters since. 919 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Addison Capital held 33,045 shares of iShares Biotechnology ETF worth $5.58M as of Q1 2026.
  • Addison Capital bought 4,569 iShares Biotechnology ETF shares in Q1 2026, an estimated $781K.
  • iShares Biotechnology ETF made up 0.99% of Addison Capital's portfolio in Q1 2026, its #26 holding.
  • Addison Capital first reported a position in iShares Biotechnology ETF in Q2 2024 and has held it in 8 quarters since.
  • 919 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Addison Capital's 13F filing for Q1 2026, filed 29 Apr 2026.